Novartis takes another stride toward Alexion's turf with PhIII PNH win

Amber Tong

Looking to break into a rare disease field that AstraZeneca subsidiary Alexion has dominated for years, Novartis says its oral drug bested anti-C5 therapies in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis takes another stride toward Alexion's turf with PhIII PNH win

Amber Tong

Sign up to read this article for free.

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA lifts hold on Entrada's Duchenne drug after two years

How AI can address ongoing challenges in the life sciences industry

No­var­tis takes an­oth­er stride to­ward Alex­ion's turf with PhI­II PNH win

Amber Tong

Sign up to read this article for free.

Pfiz­er hires ex-FDA deputy Pa­trizia Cavaz­zoni as chief med­ical of­fi­cer

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion

FDA lifts hold on En­trada's Duchenne drug af­ter two years

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

Novartis takes another stride toward Alexion's turf with PhIII PNH win

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA lifts hold on Entrada's Duchenne drug after two years

How AI can address ongoing challenges in the life sciences industry